Previous 10 | Next 10 |
Idera Pharmaceuticals (NASDAQ: IDRA ): Q1 GAAP EPS of -$0.40 beats by $0.07 . More news on: Idera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
EXTON, Pa., May 02, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for both oncology and rare disease ind...
EXTON, Pa., April 10, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drugs for both oncology and rare disease indications...
Thinly traded nano cap Idera Pharmaceuticals ( IDRA +7.7% ) is up on average volume on the heels of data from a Phase 1 clinical trial, ILLUMINATE-101 , evaluating tilsotolimod in patients with treatment-resistant solid tumors. The results are being presented today at AACR in Atlanta. ...
EXTON, Pa., April 02, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drugs for both oncology and rare disease indications...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. China's Vice Premier Liu plans to travel to the U.S. next week in what could be ano...
Idera Pharmaceuticals (NASDAQ: IDRA ): Q4 GAAP EPS of -$0.45 beats by $0.05 . More news on: Idera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
– ILLUMINATE-301 Enrollment on Track for Completion Q4 2019 – – ILLUMINATE-204 Enrollment Complete; Data Anticipated Q4 2019 – – ILLUMINATE-206 Trial Expected to Initiate Q2 2019 – – Chief Medical Officer Dr. Joanna Horo...
Bio-Path Holdings (NASDAQ: BPTH ) +55% on positive prexigebersen data. More news on: Bio-Path Holdings, Inc., Abercrombie & Fitch, China Automotive Systems, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Idera Pharmaceuticals Inc. Company Name:
IDRA Stock Symbol:
NASDAQ Market:
Idera Pharmaceuticals Inc. Website:
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023 DURHAM, N.C. and EXTON, Pa., Jan. 17, 2023 (GLOBE NEWSWI...
EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results fo...
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) ...